Skip to main content
SpringerLink
Log in

Tuberculosis

  • Chapter
  • First Online:
Management of Antimicrobials in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

  • 1748 Accesses

Abstract

Tuberculosis (TB), one of the oldest infectious diseases, still continues to be the second leading infectious cause of mortality, worldwide. The challenges posed by the AIDS epidemic and in-creasing prevalence of multidrug-resistant TB (MDR-TB) and extensively resistant TB (XDR-TB) have complicated the treatment of this otherwise curable disease. The Centers for Disease Control and Prevention (CDC) recommends several daily or intermittent regimens for drug-susceptible TB, starting with four first-line drugs and continuing with two drugs for 4–7 months with directly ob-served therapy. Second-line drugs are suggested by CDC for treat-ment of complicated MDR-TB and XDR-TB. HIV–TB co-infected patients are required to be closely monitored for interactions be-tween anti-tubercular and antiretroviral drugs. Latent TB infection is usually treated with 9 months of isoniazid or 4 months of rifampin unless the source case has drug-resistant TB.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 269.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Henry J (2007). Kaiser Family Foundation, globalhealthfacts.org (Accessed at http://globalhealthfacts.org/.)

  2. Frieden TR, Sterling TR, Munsiff SS et al. (2003). Tuberculosis. Lancet 362:887–899

    Article  PubMed  Google Scholar 

  3. Centers for Disease Control and Prevention (2005). Reported tuberculosis in the United States, 2005: Mycobacterium tuberculosis (Accessed at http://www.cdc.gov/tb/surv/surv2005/PDF/TBSurvFULLReport.pdf.)

  4. Iseman MD, Cohn DL, Sbarbaro JA (1993). Directly observed treatment of tuberculosis. We can’t afford not to try it. N Engl J Med 328:576–578

    Article  PubMed  Google Scholar 

  5. Mitnick CD, Castro KG, Harrington M et al. (2007). Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 4:e292

    Article  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention (2006). Revised definition of extensively drug-resistant tuberculosis. Morb Mortal Wkly Rep 55:1176

    Google Scholar 

  7. Centers for Disease Control and Prevention (2007). Extensively drug-resistant tuberculosis – United States, 1993–2006. Morb Mortal Wkly Rep 56:250–253

    Google Scholar 

  8. World Health Organization (2008). Anti-tuberculosis drug resistance in the world (Accessed at http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf)

  9. Centers for Disease Control and Prevention (2006). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs–worldwide, 2000–2004. Morb Mortal Wkly Rep 55:301–305

    Google Scholar 

  10. Shimao T (1987). Drug resistance in tuberculosis control. Tubercle 68:5–10

    Article  Google Scholar 

  11. Bloch AB, Simone PM, McCray E et al. (1996). Preventing multidrug-resistant tuberculosis. J Am Med Assoc 275:487–489

    Article  Google Scholar 

  12. Byrd RB, Horn BR, Solomon DA et al. (1977). Treatment of tuberculosis by the nonpulmonary physician. Ann Intern Med 86:799–802

    PubMed  Google Scholar 

  13. Mahmoudi A, Iseman MD (1993). Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. J Am Med Assoc 270:65–68

    Article  Google Scholar 

  14. Evans ME, Perkins DJ, Simmons GD (1999). Tuberculosis management practices in Kentucky: Comparison with national guidelines. South Med J 92:375–379

    Article  PubMed  Google Scholar 

  15. Centers for Disease Control and Prevention (2003). Treatment of tuberculosis. Morb Mortal Wkly Rep 52(RR-11):1–77

    Google Scholar 

  16. Cohn DL (1995). Treatment of multidrug-resistant tuberculosis. J Hosp Infect 30(Suppl):322–328

    Article  PubMed  Google Scholar 

  17. Moulding T, Dutt AK, Reichman LB (1995). Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 122:951–954

    PubMed  Google Scholar 

  18. Centers for Disease Control and Prevention (1998). Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. Morb Mortal Wkly Rep 47(RR-20):1–58

    Google Scholar 

  19. Pomerantz M, Brown JM (1997). Surgery in the treatment of multidrug-resistant tuberculosis. Clin Chest Med 18:123–130

    Article  PubMed  Google Scholar 

  20. Kim HJ, Kang CH, Kim YT et al. (2006). Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 28(3):576–580

    Article  PubMed  Google Scholar 

  21. Centers for Disease Control and Prevention (2000). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161:S221–S247

    Google Scholar 

  22. Centers for Disease Control and Prevention (2005). Guidelines for using QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. Morb Mortal Wkly Rep 54(RR-15):49–55

    Google Scholar 

  23. Centers for Disease Control and Prevention (2003). Update: Adverse event data and revised American Thoracic Society/Centers for Disease Control and Prevention recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection – United States, 2003. Morb Mortal Wkly Rep 52:735–740

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky School of Medicine, Lexington, KY, USA

    Vidya Sundareshan

  2. Lexington Veterans Affairs Medical Center and University of Kentucky School of Medicine, Lexington, KY, USA

    Martin E. Evans

Authors
  1. Vidya Sundareshan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin E. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin E. Evans .

Editor information

Editors and Affiliations

  1. Dept. Family Medicine, Medical University of South Carolina, Calhoun St. 295, Charleston, 29425, U.S.A.

    Arch G. Mainous III

  2. School of Medicine, University of California, Davis, Davis, 95616, U.S.A.

    Claire Pomeroy

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sundareshan, V., Evans, M.E. (2010). Tuberculosis. In: Mainous III, A., Pomeroy, C. (eds) Management of Antimicrobials in Infectious Diseases. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-239-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-239-1_4

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-238-4

  • Online ISBN: 978-1-60327-239-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation